Cambridge Cognition Ltd.

DUBLIN--( BUSINESS WIRE )--The "ePRO, E-Patient Diaries and eCOA - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. Global ePRO, E-Patient Diaries and eCOA Market to Reach $4.7 Billion by 2030 The global market for ePRO, E-Patient Diaries and eCOA estimated at US$1.6 Billion in the year 2022, is projected to reach a revised size of US$4.7 Billion by 2030, growing at a CAGR of 14.7% over the analysis period 2022-2030. eClinical Outcome Assessments (eCOAs), one of the segments analyzed in the report, is projected to record a 14.9% CAGR and reach US$1.4 Billion by the end of the analysis period. Growth in the Epatient Reported Outcomes (epros) segment is estimated at 16.4% CAGR for the next 8-year period. The U.S. Market is Estimated at $561.4 Million, While China is Forecast to Grow at 17.5% CAGR The ePRO, E-Patient Diaries and eCOA market in the U.S. is estimated at US$561.4 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$604.6 Million by the year 2030 trailing a CAGR of 17.5% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 12.1% and 14% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 13.3% CAGR. Key Attributes: Report Attribute Details No. of Pages 411 Forecast Period 2022 - 2030 Estimated Market Value (USD) in 2022 $1.6 Billion Forecasted Market Value (USD) by 2030 $4.7 Billion Compound Annual Growth Rate 14.4% Regions Covered Global MARKET OVERVIEW Pivotal Role of eCOA, ePRO and Patient Engagement in Transforming Patient Centricity An Introduction to ePRO, E-Patient Diaries and eCOA Pandemic Jolt Brings Strategic & Lasting Changes to Healthcare Sector COVID-19 Expedites Healthcare Ecosystem's Evolution for Better Care & Cost Savings Adoption of Telemedicine Services Accelerates Amidst the Pandemic Pandemic Impact on eCOA, ePRO Market COVID-19 Outbreak Compels Clinical Trials Industry to Move Towards ePRO eCOA Solutions Help Address Hurdles Due to COVID-19 Pandemic eCOA Playing a Part in Development of COVID-19 Vaccine Global Market Outlook eCOA: The Largest Category ePRO Offers Tremendous Opportunities in Improving Healthcare System Competition Competitive Market Presence - Strong/Active/Niche for Players Worldwide in 2023 (E) Recent Market Activity MARKET TRENDS & DRIVERS Digitalization of Healthcare Services and Rising Importance of Electronic Data Capture Technologies to Fuel Market Growth Patient Engagement Practices of the Future to be Shaped by Trends of Increased Use of Personal Devices and Passive Data Key Patient Engagement Technology Trends and Innovations eCOA & ePRO: A Powerful Duo Serving Clinical Trials with Electronic Data Collection Rise in Clinical Trials Drives Need for ePRO, ePatient Diaries, and eCOA Solutions COVID-19 Pandemic Triggers Technology Adoption in Clinical Trials Trends in Clinical Trials Space to Influence Market Demand Clinical Trials Increasingly Embraced Technology During COVID-19 Pandemic Shift towards Decentralized/Virtual Clinical Trials to Boost Market Prospects Decentralized Clinical Trials Driving Greater Demand for Patient-Centric Drug Development Role of eCOA & ePRO in Enhancing Data Accuracy of Decentralized Clinical Trials Growing Volumes of Data Generation in Decentralized Trials: A Challenge Adoption of Digital Technologies in Contract Research Organizations Bodes Well for the Market COVID-19 and Implications for Drug Development Regulations & Processes Rise in Telemedicine Services Present Market Opportunities Growing Adoption of Mobile Technologies and BYOD Trend in Healthcare Industry Boosts Market Prospects Electronic Patient Record (ePRO) Solutions Emerge as Ideal Replacements for Paper-Based PRO systems Moving over Paper Pains & Mastering the Art of Real-Time Data Collection with ePRO Delivering Better Data: A Key Benefit of ePRO Factors Ensuring Success of ePRO Implementations ePatient Reported Outcomes (PROs) Gain Importance in Oncology Studies Advances in ePRO Technologies Promise Better Clinical Decision Making in Healthcare Systems Integrating AI into ePRO Improves the Efficiency of ePRO Data Collection and Assessment Data Integrity, Security & Privacy: Key Priorities for ePRO Solutions Electronic Clinical Outcome Assessment Solution (eCOA) Market: Poised for Growth eCOA Grants The Best Route to Improve Data Quality & Patient Experience for Clinical Trials Benefits Offered by eCOA Systems over the Paper-Based Systems in Trials How to Successfully Implement eCOA Systems in Clinical Trials? New Technologies & Approaches with Potential to Augment Statistical Prowess of eCOA Technological Trends Transforming eCOA Solutions Market Future Trends in eCOA Market: A Review eCOA Proves Beneficial in Addressing Clinical Trial Challenges During COVID-19 Pandemic UAT, Challenges and Embedded UAT for eCOAs Benefits of BYOD for eCOAs E-Patient Diaries: Significant Advantages over Paper Diaries to Drive Market Major Benefits of ePatient Diary eCOA & ePRO to Help Mental Health Research Shed the Taboo Status & Move Forward Intriguing Perks of eCOA & ePRO for Mental Health Research Increase in Healthcare Spending to Propel Demand Increasing Burden of Chronic Diseases and Focus on Drug Development, Therapies and Vaccines Boost Market Challenges Facing Companies Implementing eCOA, ePRO & Patient-Centric Clinical Trials FOCUS ON SELECT PLAYERS (Total 85 Featured) Dassault Systemes SE (3DS) Almac Group Clinical Ink, Inc. Criterium, Inc. Dacima Software, Inc. Anju Software ArisGlobal LLC Cogstate Ltd. Cambridge Cognition Ltd. CliniOps Inc., Castor EDC ClinCapture Clinion Adelphi Group Crucial Data Solutions For more information about this report visit https://www.researchandmarkets.com/r/2dq4rn About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Taiwan clears VUNO's AI fundus analysis tool South Korean firm VUNO has gained the approval of Taiwan's Food and Drug Administration to market its AI fundus analysis software. VUNO Med-Fundus AI analyses images of the fundus to quickly detect locations of lesions indicative of retinal diseases, including diabetic retinopathy, macular disease and glaucoma. This latest certification follows Taiwan FDA's clearance for its other AI products, VUNO-Med Chest X-ray and VUNO-Med Bone Age. Just two months ago, VUNO obtained Singapore's clearance for VUNO Med-Fundus AI. Study validates AIRS Medical's AI solution for denoising 3D MR images AIRS Medical, a medical AI startup from South Korea, has recently proved in a study the capability of its AI-powered MRI reconstruction solution, SwiftMR, to denoise and greatly improve the quality of 3D MR images. Based on its findings, a deep neural network-based noise reduction and image quality improvement tool outperformed the conventional magnetisation-prepared rapid gradient-echo (MP-RAGE) sequence in improving MR image quality. "We are very pleased that we have proved SwiftMR contributes to not only reducing time but also [helping] make images great, eventually [helping] radiologists read images with confidence," said AIRS Medical CEO Dr Hyeseong Lee. Qure.ai packages solutions using NVIDIA's MONAI kit Indian health technology startup Qure.ai is one of the early adopters of NVIDIA's latest open-source framework for deploying AI medical imaging applications. The MONAI Application Packages (MAP) simplify the process of deploying an AI model in an existing healthcare ecosystem. Qure.ai is now packaging its AI solutions for deployment using MAPs, accelerating its clinical impact, according to NVIDIA. UK-based Cambridge Cognition brings brain health solutions to China London-listed Cambridge Cognition, a provider of cognitive assessment test solutions, has entered into a new partnership to bring its digital health offerings to China. The company recently signed a 10-year exclusive licensing deal and strategic partnership with Luca Healthcare, a local developer of digital health assessment tools. Luca will be making Cambridge Cognition's CANTAB suite of digital brain health tests available in China via its LucaPlex platform. "China has over 265 million people aged 60 years and above, of which 40 million people have mild cognitive impairment and 15 million people with a form of dementia. With neurodegenerative diseases, early diagnosis is the key to managing disease progression. We will leverage Cambridge Cognition's research, scientific know-how, and digital technology to make available advanced cognitive assessment tools for the clinical trials market and the healthcare market in China," said Luca CEO Echo Chen.

SHANGHAI, Nov. 28, 2022 /PRNewswire/ -- Cambridge Cognition, a leading technology company, which develops and markets digital solutions to assess brain health, and Luca Healthcare, China's category leader in developing and commercializing clinically validated digital health solutions, today announces a strategic partnership and a 10-year exclusive licensing agreement to commercialize Cambridge Cognition's suite of cognitive assessment tools in the China market. Generally considered the gold standard in cognitive assessment tools, Cambridge Cognition's technologies have been used in over 2,500 studies, in more than 100 countries and 50 languages to assess over 1 million patients. The company remains at the forefront of research in the field, investing millions of pounds each year in cutting-edge new developments. "We are delighted to enter this partnership with Luca Healthcare to deploy Cambridge Cognition's products in China. For over 30 years, our technology has been at the forefront of scientific discovery, delivering value to research institutions, healthcare providers and pharmaceutical and biotechnology companies worldwide", said Matthew Stork, Chief Executive Officer of Cambridge Cognition, "and we plan to work closely with Luca Healthcare to make these solutions available in clinical trials and for patients across China." A key component of this partnership brings the CANTAB™ suite of tools to the China commercial market. Originally developed at the University of Cambridge, CANTAB™ includes highly sensitive, precise, and objective measures of cognitive function. CANTAB™ tests have demonstrated sensitivity to detecting changes in performance across a wide range of cognitive functions, including working memory, learning, executive function, visual, verbal, and episodic memory. The assessments themselves are language-independent and the instructions are already available in Chinese. Cognitive assessments are invaluable tools for understanding the role of specific brain functions across a range of disorders and diseases, giving insight into underlying causes, identifying ways to detect the earliest symptoms, and evaluating the effects of interventions designed to improve brain health. Luca plans to make these tools available to the China market through the LucaPlex® platform that serves their pharmaceutical and commercial partners in China. Cambridge Cognition's assessments are hosted in a secure cloud-based server in China and can be run seamlessly within the LucaPlex® using APIs. "China has over 265 million people aged 60 years and above, of which 40 million people have mild cognitive impairment with 15 million people having a form of dementia. With neurodegenerative diseases, early diagnosis is the key to managing disease progression. We will leverage Cambridge Cognition's research, scientific know-how, and digital technology to make available advanced cognitive assessment tools for the clinical trials market and the healthcare market in China," said Echo Chen, Ph.D., Chief Executive Officer of Luca Healthcare. "We are absolutely thrilled to be working with a great team and the most validated cognition assessment tool in the world. Luca's mission is to make healthcare more affordable and more accessible; this partnership certainly gives us an opportunity to do that for those impacted by neurodegenerative disorders in China." About Cambridge Cognition Cambridge Cognition is a technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The Company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries. About Luca Healthcare Luca Healthcare's mission is to provide affordable, accessible, and clinically validated software-based screening, tracking, management, and treatment solutions to a wider patient population in China through digital innovation and global partnerships. The company develops and in-licenses clinically validated digital assessment tools using novel digital biomarkers to measure and to intervene diseases and conditions in respiratory, neurodegenerative, cardiovascular, and ophthalmology therapeutic areas. For additional inquiries, please contact: Sally Jennings Cambridge Cognition Email: [email protected] Phone: +44 01223810700 Garry Wang Luca Healthcare Email: [email protected] Phone: +86 13816843646 SOURCE Luca Healthcare